Malaysian COVID-19 Anosmia Study (Phase 1) - A Nationwide Multicentre Cross-Sectional Study

NCT ID: NCT04390165

Last Updated: 2021-02-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

498 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-06-06

Study Completion Date

2020-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Malaysian COVID-19 Anosmia Study is a nationwide multicentre observational study to investigate the prevalence and characteristics of olfactory and gustatory/taste disturbances in COVID-19 infection in Malaysia, and to evaluate the predictive value of screening for these symptoms in COVID-19 infection.

This study consists of two phases: the first phase is a cross-sectional study and the second phase is a case-control study. The cross-sectional study is described here (the case-control study is described in a separate ClinicalTrials.gov record).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The world is currently in the midst of the Coronavirus 2019 (COVID-19) pandemic that is caused by a novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). According to published cohort studies on COVID-19 infected patients, the most prevalent symptoms consist of fever, dry cough, dyspnoea, sputum production, myalgia, arthralgia, headache, diarrhoea, and sore throat. Recently, there have been concerns of significant viral transmission through asymptomatic, pre-symptomatic or even mildly symptomatic patients.

There is increasing anecdotal evidence from patients and healthcare professionals highlighting isolated loss of sense of smell (anosmia) and taste disturbances (dysgeusia) as atypical symptoms of COVID-19 infection in otherwise asymptomatic patients. In parallel, expert statements from the British Association of Otorhinolaryngology-Head \& Neck Surgery (ENT UK), British Rhinological Society, and the American Association of Otolaryngology-Head \& Neck Surgery (AAO-HNS) have suggested that olfactory and taste disturbances could be a clinical feature of COVID-19 infection.

Rapidly emerging evidence from Europe, the United Kingdom and the United States have found olfactory and taste disturbances to be highly prevalent in patients diagnosed with COVID-19. In contrast, there is currently limited evidence from Asia on the prevalence of these symptoms in COVID-19 infection.

The aim of this cross-sectional study is to study the prevalence and characteristics of olfactory and taste disturbance in patients with COVID-19 infection in Malaysia. COVID-19 positive patients will be recruited from participating Malaysian Ministry of Health-designated COVID-19 treating hospitals across the country. Participants will answer an online questionnaire to evaluate and characterise these symptoms.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

SARS-CoV Infection COVID-19 Anosmia Dysgeusia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Malaysian COVID-19 Cohort

A cohort of COVID-19 positive patients will be recruited from participating Malaysian Ministry of Health-designated COVID-19 treating hospitals across the country.

Patient-Reported Online Questionnaire on Olfactory & Taste Disturbances

Intervention Type OTHER

This is an online patient-reported questionnaire that examines the presence or absence of olfactory and taste disturbances, the onset of olfactory and taste disturbances in relation to other COVID-19 symptoms, and the temporal evolution of the severity of olfactory and taste disturbances. The occurrence of ear symptoms in COVID-19 infection will also be evaluated in this questionnaire as a secondary outcome. The questionnaire will also have questions relating to the patient's underlying health conditions, risk factors for COVID-19 infection, and demographics.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Patient-Reported Online Questionnaire on Olfactory & Taste Disturbances

This is an online patient-reported questionnaire that examines the presence or absence of olfactory and taste disturbances, the onset of olfactory and taste disturbances in relation to other COVID-19 symptoms, and the temporal evolution of the severity of olfactory and taste disturbances. The occurrence of ear symptoms in COVID-19 infection will also be evaluated in this questionnaire as a secondary outcome. The questionnaire will also have questions relating to the patient's underlying health conditions, risk factors for COVID-19 infection, and demographics.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age at least 18 years old
2. Laboratory confirmed COVID-19 infection \[Reverse Transcription Polymerase Chain Reaction (RT-PCR)\]
3. Patients clinically able to answer the questionnaire

Exclusion Criteria

1. Patients with olfactory or taste/gustatory disorders before the COVID-19 epidemic
2. Patients without a laboratory-confirmed COVID-19 diagnosis
3. Patients in intensive care unit at the time of study
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hospital Tuanku Fauziah, Kangar, Perlis

UNKNOWN

Sponsor Role collaborator

Penang Hospital, Malaysia

OTHER_GOV

Sponsor Role collaborator

Hospital Raja Permaisuri Bainun

OTHER_GOV

Sponsor Role collaborator

Hospital Sungai Buloh, Selangor

UNKNOWN

Sponsor Role collaborator

Kuala Lumpur General Hospital

OTHER_GOV

Sponsor Role collaborator

Hospital Tuanku Jaafar, Seremban, Negeri Sembilan

UNKNOWN

Sponsor Role collaborator

Hospital Melaka, Melaka

UNKNOWN

Sponsor Role collaborator

Hospital Enche Besar Hajjah Khalsom, Kluang, Johor

UNKNOWN

Sponsor Role collaborator

Hospital Raja Perempuan Zainab II, Kota Bahru, Kelantan

UNKNOWN

Sponsor Role collaborator

Hospital Sultanah Nur Zahirah, Kuala Terengganu

OTHER_GOV

Sponsor Role collaborator

Hospital Tengku Ampuan Afzan, Kuantan, Pahang

UNKNOWN

Sponsor Role collaborator

Sarawak General Hospital

OTHER

Sponsor Role collaborator

Hospital Queen Elizabeth, Malaysia

OTHER_GOV

Sponsor Role collaborator

Hospital Sultanah Bahiyah

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Siti Sabzah bt Mohd Hashim, MD, MS (ORL-HNS)

Head of Otorhinolaryngology Service, Ministry of Health, Malaysia & Senior Consultant Otorhinolaryngologist

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Siti Sabzah Mohd Hashim, MD MS

Role: STUDY_CHAIR

Hospital Sultanah Bahiyah

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital Enche' Besar Hajjah Khalsom

Kluang, Johor, Malaysia

Site Status

Hospital Sultanah Bahiyah

Alor Star, Kedah, Malaysia

Site Status

Hospital Raja Perempuan Zainab II

Kota Bharu, Kelantan, Malaysia

Site Status

Hospital Tuanku Jaafar

Seremban, Negeri Sembilan, Malaysia

Site Status

Hospital Tengku Ampuan Afzan

Kuantan, Pahang, Malaysia

Site Status

Hospital Raja Permaisuri Bainun

Ipoh, Perak, Malaysia

Site Status

Hospital Tuanku Fauziah

Kangar, Perlis, Malaysia

Site Status

Penang Hospital

George Town, Pulau Pinang, Malaysia

Site Status

Hospital Queen Elizabeth

Kota Kinabalu, Sabah, Malaysia

Site Status

Sarawak General Hospital

Kuching, Sarawak, Malaysia

Site Status

Hospital Sungai Buloh

Sungai Buloh, Selangor, Malaysia

Site Status

Hospital Sultanah Nur Zahirah

Kuala Terengganu, Terengganu, Malaysia

Site Status

Kuala Lumpur General Hospital

Kuala Lumpur, , Malaysia

Site Status

Hospital Melaka

Malacca, , Malaysia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Malaysia

References

Explore related publications, articles, or registry entries linked to this study.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.

Reference Type BACKGROUND
PMID: 31986264 (View on PubMed)

Giacomelli A, Pezzati L, Conti F, Bernacchia D, Siano M, Oreni L, Rusconi S, Gervasoni C, Ridolfo AL, Rizzardini G, Antinori S, Galli M. Self-reported Olfactory and Taste Disorders in Patients With Severe Acute Respiratory Coronavirus 2 Infection: A Cross-sectional Study. Clin Infect Dis. 2020 Jul 28;71(15):889-890. doi: 10.1093/cid/ciaa330. No abstract available.

Reference Type BACKGROUND
PMID: 32215618 (View on PubMed)

Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, Chang J, Hong C, Zhou Y, Wang D, Miao X, Li Y, Hu B. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol. 2020 Jun 1;77(6):683-690. doi: 10.1001/jamaneurol.2020.1127.

Reference Type BACKGROUND
PMID: 32275288 (View on PubMed)

Lechien JR, Chiesa-Estomba CM, De Siati DR, Horoi M, Le Bon SD, Rodriguez A, Dequanter D, Blecic S, El Afia F, Distinguin L, Chekkoury-Idrissi Y, Hans S, Delgado IL, Calvo-Henriquez C, Lavigne P, Falanga C, Barillari MR, Cammaroto G, Khalife M, Leich P, Souchay C, Rossi C, Journe F, Hsieh J, Edjlali M, Carlier R, Ris L, Lovato A, De Filippis C, Coppee F, Fakhry N, Ayad T, Saussez S. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol. 2020 Aug;277(8):2251-2261. doi: 10.1007/s00405-020-05965-1. Epub 2020 Apr 6.

Reference Type BACKGROUND
PMID: 32253535 (View on PubMed)

Kaye R, Chang CWD, Kazahaya K, Brereton J, Denneny JC 3rd. COVID-19 Anosmia Reporting Tool: Initial Findings. Otolaryngol Head Neck Surg. 2020 Jul;163(1):132-134. doi: 10.1177/0194599820922992. Epub 2020 Apr 28.

Reference Type BACKGROUND
PMID: 32340555 (View on PubMed)

Yan CH, Faraji F, Prajapati DP, Boone CE, DeConde AS. Association of chemosensory dysfunction and COVID-19 in patients presenting with influenza-like symptoms. Int Forum Allergy Rhinol. 2020 Jul;10(7):806-813. doi: 10.1002/alr.22579. Epub 2020 Jun 1.

Reference Type BACKGROUND
PMID: 32279441 (View on PubMed)

Spinato G, Fabbris C, Polesel J, Cazzador D, Borsetto D, Hopkins C, Boscolo-Rizzo P. Alterations in Smell or Taste in Mildly Symptomatic Outpatients With SARS-CoV-2 Infection. JAMA. 2020 May 26;323(20):2089-2090. doi: 10.1001/jama.2020.6771.

Reference Type BACKGROUND
PMID: 32320008 (View on PubMed)

Lee SH, Yeoh ZX, Sachlin IS, Gazali N, Soelar SA, Foo CY, Low LL, Syed Alwi SB, Tengku Kamalden TMI, Shanmuganathan J, Zaid M, Wong CY, Chua HH, Yusuf S, Muhamad D, Devesahayam PR, Ker HB, Salahuddin Z, Mustafa M, Sawali H, Lee HG, Din S, Misnan NA, Mohamad A, Ismail MN, Periasamy C, Chow TS, Krishnan EK, Leong CL, Lim LPF, Zaidan NZ, Ibrahim MZ, Abd Wahab S, Mohd Hashim SS; Malaysian COVID-19 Anosmia Research Group. Self-reported symptom study of COVID-19 chemosensory dysfunction in Malaysia. Sci Rep. 2022 Feb 8;12(1):2111. doi: 10.1038/s41598-022-06029-6.

Reference Type DERIVED
PMID: 35136124 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

https://www.entnet.org/content/aao-hns-anosmia-hyposmia-and-dysgeusia-symptoms-coronavirus-disease

AAO-HNS: Anosmia, Hyposmia, and Dysgeusia Symptoms of Coronavirus Disease \| American Academy of Otolaryngology-Head and Neck Surgery

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NMRR-20-934-54803

Identifier Type: OTHER

Identifier Source: secondary_id

MCO-001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.